Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0264-410x(97)00240-5 | DOI Listing |
Front Public Health
December 2024
Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Maternal immunization is a valuable tool for protecting mother and unborn child from vaccine-preventable diseases. However, the implementation of strategies for vaccinating pregnant women has only recently gained traction. This work is aimed at providing an overview of European vaccination strategies and gathering evidence on interventions enhancing vaccination knowledge, attitudes, and behaviors (KAB) in pregnant women.
View Article and Find Full Text PDFVaccines (Basel)
October 2024
Serum Institute of India Pvt Ltd., Pune 411 028, India.
Multivalent meningococcal conjugate vaccines are a significant focus for the scientific community in light of the WHO's mission to defeat meningitidis by 2030. Well-known meningococcal vaccines such as MenAfriVac, Nimenrix, Menveo, and MenQuadfi are licensed in various parts of the world and have been successful. Recently, the World Health Organization (WHO) qualified MenFive (meningococcal A, C, Y, W, and X) conjugate vaccine, further enhancing the battery of vaccines against meningitis.
View Article and Find Full Text PDFDiagnostics (Basel)
October 2024
Microbiology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Infect Dis Rep
September 2024
Italian College of General Practitioners and Primary Care, 50142 Florence, Italy.
: In recent years, Europe has experienced a significant increase in pertussis cases. One reason behind this rise is the decline in diphtheria-tetanus-pertussis (dTap) booster coverage among adults. Currently, Italy lacks a reliable monitoring system to track pertussis infections and vaccine coverage among adults.
View Article and Find Full Text PDFInt Rev Immunol
September 2024
Amity Institute of Microbial Technology, Amity University Rajasthan, Jaipur, India.
Aluminum salt-based adjuvants like alum, alhydrogel and Adju-Phos are by far the most favored clinically approved vaccine adjuvants. They have demonstrated excellent safety profile and currently used in vaccines against diphtheria, tetanus, pertussis, hepatitis B, anthrax etc. These vaccinations cause minimal side effects like local inflammation at the injection site.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!